Tumor Biology

, Volume 35, Issue 8, pp 8017–8022 | Cite as

CD243 gene polymorphism significantly associated with breast cancer susceptibility

  • Weirong Yao
  • Rongzeng Yan
  • Lin Ma
  • Huiping Wan
  • Yanmin Yu
  • Xia Cheng
  • Yingliang Li
Research Article


We aimed to obtain a summary risk estimate for CD243 gene polymorphism associated with breast cancer. A total of nine case–control studies, including 5,073 cancer patients and 7,498 control subjects, were pooled in our fixed effects meta-analysis of the association between CD243 gene polymorphism and risk of breast cancer. All data were analyzed by using Stata software (version 12.0). We found significant risk effects under TT vs. TC + CC genetic model [odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.01–1.18, P = 0.516], but not in other comparisons. Stratifying the pooled data by ethnicity and source of controls revealed that the association between the T allele and an increased risk of breast cancer was more pronounced among Asians (TT vs. CC: OR = 1.26, 95 % CI = 1.02–1.57, P = 0.720; TT vs. TC + CC: OR = 1.31, 95 % CI = 1.07–1.61, P = 0.708) and hospital-based studies (TT vs. CC: OR = 1.25, 95 % CI = 1.02–1.53, P = 0.877; TT vs. TC + CC: OR = 1.27, 95 % CI = 1.05–1.53, P = 0.540). No notable heterogeneity was indicated across studies. Our meta-analysis demonstrates that CD243 gene polymorphism may act as a predisposition factor for breast cancer, particularly in Asian populations.


CD243 polymorphism Breast cancer Risk 


Conflicts of interest



  1. 1.
    Smigal C et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168–83.PubMedCrossRefGoogle Scholar
  2. 2.
  3. 3.
    Jemal A et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J. 2004;4(3):143–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Lester J. Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs. 2007;11(5):619–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother. 2007;8(2):119–27.PubMedCrossRefGoogle Scholar
  7. 7.
    Fossland VS et al. Genetic issues in patients with breast cancer. Surg Oncol Clin N Am. 2009;18(1):53–71. viii.PubMedCrossRefGoogle Scholar
  8. 8.
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.PubMedCrossRefGoogle Scholar
  9. 9.
    Gervasini G et al. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer. 2006;107(12):2850–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Jamroziak K et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72(5):314–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Sohn JW et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol. 2006;36(3):137–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Kurzawski M et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol. 2005;61(5–6):389–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer. 2003;10(1):43–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997;89(13):917–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Kroetz DL et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13(8):481–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Kafka A et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003;22(5):1117–21.PubMedGoogle Scholar
  18. 18.
    Turgut S et al. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res. 2007;38(5):539–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Henriquez-Hernandez LA et al. Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case–control study. Oncol Rep. 2009;22(6):1425–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Tatari F et al. Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol. 2009;28(5):259–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Cizmarikova M et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010;10(1):62–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Lu PH et al. Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat. 2011;125(2):537–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang J, Wang B, Bi J. Significant association between ABCB1 gene C3435T polymorphism and breast cancer risk. Breast Cancer Res Treat. 2011;126(3):815–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang J et al. MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case–control studies. J Cancer Res Clin Oncol. 2012;138(6):979–89.PubMedCrossRefGoogle Scholar
  25. 25.
    Sheng X et al. MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case–control studies. Mol Biol Rep. 2012;39(7):7237–49.PubMedCrossRefGoogle Scholar
  26. 26.
    Wang LH et al. The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case–control studies. Cancer Cell Int. 2013;13(1):46.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRefGoogle Scholar
  28. 28.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMedGoogle Scholar
  29. 29.
    Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Nordgard SH et al. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics. 2007;17(2):127–36.PubMedCrossRefGoogle Scholar
  31. 31.
    George J et al. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer. 2009;9(3):161–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res. 2010;9(1):34–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Wu H et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol. 2012;138(9):1449–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Abbas S, Beckman L, Chang-Claude J, Hein R, Kropp S, Parthimos M, et al. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat. 2010;120(3):727–36.CrossRefGoogle Scholar
  35. 35.
    Cancer C. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360(9328):187–95.CrossRefGoogle Scholar
  36. 36.
    Parkin DM et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Radiation OncologyChinese PLA General HospitalBeijingChina
  2. 2.Department of OncologyPeople’s Hospital of Jiangxi ProvinceNanchangChina
  3. 3.Chinese People’s Armed Police Forces Jiangxi General HospitalNanchangChina
  4. 4.Department of General SurgeryThe First Affiliated Hospital of Nanchang UniversityNanchangChina

Personalised recommendations